Reports › Company profiles › Cipla Limited
Cipla Limited
Sector: Pharmaceuticals | HQ: Mumbai, Maharashtra | Founded: 1935 | Employees: ~25,000
Listed as: NSE / BSE listed; Nifty 50 constituent | NSE / BSE | Ticker: CIPLA.NS | Website →
Live stock price (NSE)
₹1,305
-42.10 (-3.13%) today
Source: Yahoo Finance · Refreshed every 15 minutes · Fetched 11/5/2026, 4:34:40 pm IST. For information only; not investment advice.
Key people
- Y K Hamied (Non-Executive Chairman)
- Umang Vohra (CEO and MD)
Company overview
Cipla Limited is one of India's top-3 pharmaceutical companies by revenue, with a 90-year heritage going back to 1935. Headquartered in Mumbai with operations across India, USA, South Africa, Europe, and Emerging Markets, Cipla operates 47 manufacturing facilities globally. FY25 revenue was approximately ₹27,500 crore. The company is known for inhaled respiratory medicines, antiretrovirals (ARV) for HIV/AIDS treatment, and a deep generic and complex-generic pipeline.
Business model
Cipla operates four reporting segments: One India (domestic formulations), North America (US generics and specialty), South Africa, and Emerging Markets and Europe. The Indian business contributes the largest share of EBITDA. The US business is in growth phase with complex generics and inhalation launches.
Operating segments
One India
India domestic branded generics. Strong respiratory and chronic-therapy franchise.
North America
US generics, inhalation, peptides, and complex generics.
South Africa
Cipla Medpro acquired in 2013; leading position in South African pharma.
Emerging Markets and Europe
ARV programmes in Africa, Latin America, Middle East.
Financial performance and recent trajectory
Cipla reported FY25 revenue of ₹27,500 crore with EBITDA margin in the 25-27 percent range. R&D spend is approximately 6-7 percent of revenue.
Stock performance and shareholder context
Cipla (NSE: CIPLA, BSE: 500087) is a Nifty 50 constituent. Hamied family holds approximately 33 percent.
12-month price trajectory
Monthly closes over the last 12 months. Source: Yahoo Finance.
Competitive position
Top-3 Indian pharma by revenue. Leader in respiratory (inhalers) and HIV/AIDS ARV. Top-10 global respiratory player.
Key risks
US FDA inspection findings; US complex-generic competition; INR-USD volatility; India price regulation.
Outlook
Strong outlook on respiratory and complex-generic launches through FY28.
KAMRIT point of view
Building or competing with Cipla?
KAMRIT advises promoters, family offices, and global enterprises evaluating greenfield entry into the pharmaceuticals sector. Our Bankable DPR with Cost Model and ROI benchmarks your project economics against the listed-company cost structure of Cipla and peers. The Execution Partnership tier covers everything from incorporation through commissioning. A 20-minute scoping call with our partners is free.
Related KAMRIT project reports
These reports use Cipla Limited in benchmarking and competitive analysis sections.
Pharmaceutical Formulations Manufacturing Plant Project Report
Pharma & Healthcare · Market ₹4.5 lakh crore · CAGR 11.8%
API / Bulk Drug Manufacturing Plant Project Report
Pharma & Healthcare · Market ₹2.2 lakh crore · CAGR 13.8%
Medical Devices Manufacturing Plant Project Report
Pharma & Healthcare · Market ₹95,000 crore · CAGR 15.4%
Disclaimer: This profile is compiled by KAMRIT Financial Services LLP for educational and benchmarking purposes only. It is not investment advice, a recommendation to buy or sell securities, or a solicitation. Stock data is provided by Yahoo Finance and may be delayed by up to 20 minutes. Company financial commentary draws on publicly available filings, exchange disclosures, and KAMRIT industry research. Readers should consult a SEBI-registered investment adviser before making investment decisions. KAMRIT is a financial services and compliance firm, not a SEBI-registered investment adviser.